Voloridge Investment Management
MCRB icon

Voloridge Investment Management’s Seres Therapeutics MCRB Stock Holding History

Voloridge Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,884
Closed -$747K – 1532
2022
Q2 		$747K Sell
10,884
-10,099
-48% -$870K ﹤0.01% 1250
2022
Q1 		$2.99M Sell
20,983
-611
-3% -$94K 0.02% 823
2021
Q4 		$3.6M Sell
21,594
-18,875
-47% -$3M 0.02% 838
2021
Q3 		$5.63M Buy
+40,469
New +$7.92M 0.04% 632
2020
Q4 		– Sell
-532
Closed -$301K – 1468
2020
Q3 		$301K Buy
+532
New +$177K ﹤0.01% 1155

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Voloridge Investment Management's MCRB Position: Q3 2022 in Review

Voloridge Investment Management sold out of Seres Therapeutics (MCRB) in Q3 2022, closing a stake of 10,884 shares — an estimated $747K sold.

Voloridge Investment Management first reported a position in MCRB in Q3 2020 and held it in 5 quarters. The position peaked at $5.63M in Q3 2021. 119 funds tracked by Wall St. Rank hold MCRB as of Q3 2022.

  • Voloridge Investment Management reported no remaining Seres Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Voloridge Investment Management sold 10,884 Seres Therapeutics shares in Q3 2022, an estimated $747K.
  • Voloridge Investment Management first reported a position in Seres Therapeutics in Q3 2020 and held it in 5 quarters.
  • Voloridge Investment Management's Seres Therapeutics position peaked at $5.63M in Q3 2021.
  • 119 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2022.

Based on Voloridge Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.